MovDisordV3, Main, Exploration, bibRecord, 001050

Nicotine as a Potential Neuroprotective Agent for Parkinson's Disease

Identifieur interne : 001050 ( Main/Exploration ); précédent : 001049; suivant : 001051

Nicotine as a Potential Neuroprotective Agent for Parkinson's Disease

Auteurs : Maryka Quik [États-Unis] ; Xiomara A. Perez [États-Unis] ; Tanuja Bordia [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2012.

RBID : Pascal:12-0315939

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Nicotine, Neuroprotecteur.

English descriptors

KwdEn :
- Animals, Corpus Striatum (pathology), Disease Models, Animal, Humans, Nervous system diseases, Neuroprotective Agents, Neuroprotective agent, Nicotine, Nicotine (therapeutic use), Nicotinic Agonists (therapeutic use), Parkinson Disease (prevention & control), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (prevention & control), Parkinson disease, Receptors, Nicotinic (drug effects), Signal Transduction (drug effects), Smoking (epidemiology), Substantia Nigra (pathology).
MESH :
- chemical , drug effects : Receptors, Nicotinic.
- chemical , therapeutic use : Nicotine, Nicotinic Agonists.
- chemical : Neuroprotective Agents.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Signal Transduction.
- epidemiology : Smoking.
- pathology : Corpus Striatum, Substantia Nigra.
- prevention & control : Parkinson Disease, Parkinson Disease, Secondary.
- Animals, Disease Models, Animal, Humans.

Abstract

Converging research efforts suggest that nicotine and other drugs that act at nicotinic acetylcholine receptors (nAChRs) may be beneficial in the management of Parkinson's disease. This idea initially stemmed from the results of epidemiological studies that demonstrated that smoking is associated with a decreased incidence of Parkinson's disease. The subsequent finding that nicotine administration protected against nigrostriatal damage in parkinsonian animal models led to the idea that nicotine in tobacco products may contribute to this apparent protective action. Nicotine most likely exerts its effects by interacting at nAChRs. Accumulating research indicates that multiple subtypes containing nAChRs, including α4β2, α6β2, and/or α7, may be involved. Stimulation of nAChRs initially activates various intracellular transduction pathways primarily via alterations in calcium signaling. Consequent adaptations in immune responsiveness and trophic factors may ultimately mediate nicotine's ability to reduce/halt the neuronal damage that arises in Parkinson's disease. In addition to a potential neuroprotective action, nicotine also has antidepressant properties and improves attention/cognition. Altogether, these findings suggest that nicotine and nAChR drugs represent promising therapeutic agents for the management of Parkinson's disease.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685410

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Nicotine as a Potential Neuroprotective Agent for Parkinson's Disease</title>
<author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Health Sciences, SRI International</s1>
<s2>Menlo Park, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Perez, Xiomara A" sort="Perez, Xiomara A" uniqKey="Perez X" first="Xiomara A." last="Perez">Xiomara A. Perez</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Health Sciences, SRI International</s1>
<s2>Menlo Park, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bordia, Tanuja" sort="Bordia, Tanuja" uniqKey="Bordia T" first="Tanuja" last="Bordia">Tanuja Bordia</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Health Sciences, SRI International</s1>
<s2>Menlo Park, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0315939</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0315939 INIST</idno>
<idno type="RBID">Pascal:12-0315939</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000142</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002B72</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000123</idno>
<idno type="wicri:doubleKey">0885-3185:2012:Quik M:nicotine:as:a</idno>
<idno type="wicri:Area/Main/Merge">001102</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685410</idno>
<idno type="RBID">PMC:3685410</idno>
<idno type="wicri:Area/Pmc/Corpus">000269</idno>
<idno type="wicri:Area/Pmc/Curation">000269</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000174</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000D50</idno>
<idno type="wicri:Area/PubMed/Curation">000D50</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000D19</idno>
<idno type="wicri:Area/Ncbi/Merge">003696</idno>
<idno type="wicri:Area/Ncbi/Curation">003696</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003696</idno>
<idno type="wicri:doubleKey">0885-3185:2012:Quik M:nicotine:as:a</idno>
<idno type="wicri:Area/Main/Merge">000D09</idno>
<idno type="wicri:Area/Main/Curation">001050</idno>
<idno type="wicri:Area/Main/Exploration">001050</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Nicotine as a Potential Neuroprotective Agent for Parkinson's Disease</title>
<author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Health Sciences, SRI International</s1>
<s2>Menlo Park, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Perez, Xiomara A" sort="Perez, Xiomara A" uniqKey="Perez X" first="Xiomara A." last="Perez">Xiomara A. Perez</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Health Sciences, SRI International</s1>
<s2>Menlo Park, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bordia, Tanuja" sort="Bordia, Tanuja" uniqKey="Bordia T" first="Tanuja" last="Bordia">Tanuja Bordia</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Health Sciences, SRI International</s1>
<s2>Menlo Park, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Corpus Striatum (pathology)</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
<term>Nervous system diseases</term>
<term>Neuroprotective Agents</term>
<term>Neuroprotective agent</term>
<term>Nicotine</term>
<term>Nicotine (therapeutic use)</term>
<term>Nicotinic Agonists (therapeutic use)</term>
<term>Parkinson Disease (prevention & control)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (prevention & control)</term>
<term>Parkinson disease</term>
<term>Receptors, Nicotinic (drug effects)</term>
<term>Signal Transduction (drug effects)</term>
<term>Smoking (epidemiology)</term>
<term>Substantia Nigra (pathology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Nicotinic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Nicotine</term>
<term>Nicotinic Agonists</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Smoking</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Corpus Striatum</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Parkinson Disease</term>
<term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Nicotine</term>
<term>Neuroprotecteur</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Converging research efforts suggest that nicotine and other drugs that act at nicotinic acetylcholine receptors (nAChRs) may be beneficial in the management of Parkinson's disease. This idea initially stemmed from the results of epidemiological studies that demonstrated that smoking is associated with a decreased incidence of Parkinson's disease. The subsequent finding that nicotine administration protected against nigrostriatal damage in parkinsonian animal models led to the idea that nicotine in tobacco products may contribute to this apparent protective action. Nicotine most likely exerts its effects by interacting at nAChRs. Accumulating research indicates that multiple subtypes containing nAChRs, including α4β2, α6β2, and/or α7, may be involved. Stimulation of nAChRs initially activates various intracellular transduction pathways primarily via alterations in calcium signaling. Consequent adaptations in immune responsiveness and trophic factors may ultimately mediate nicotine's ability to reduce/halt the neuronal damage that arises in Parkinson's disease. In addition to a potential neuroprotective action, nicotine also has antidepressant properties and improves attention/cognition. Altogether, these findings suggest that nicotine and nAChR drugs represent promising therapeutic agents for the management of Parkinson's disease.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Californie"><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name>
</region>
<name sortKey="Bordia, Tanuja" sort="Bordia, Tanuja" uniqKey="Bordia T" first="Tanuja" last="Bordia">Tanuja Bordia</name>
<name sortKey="Perez, Xiomara A" sort="Perez, Xiomara A" uniqKey="Perez X" first="Xiomara A." last="Perez">Xiomara A. Perez</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001050 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001050 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:12-0315939
   |texte=   Nicotine as a Potential Neuroprotective Agent for Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Nicotine as a Potential Neuroprotective Agent for Parkinson's Disease

Nicotine as a Potential Neuroprotective Agent for Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.